Healthcare giant Merck & Co., Inc. reported Tuesday a profit for the first quarter that declined 44 percent from last year, hurt by higher charges and R&D costs as well as a revenue decline. However, stripping down charges, adjusted earnings per share topped analysts’ expectations, as did quarterly revenues thanks in part to higher sales of diabetes drug Januvia.